That is the question any prudent investor would ask. The potential return is enormous. What is the catch? It would be different if we, through buying shares, were actually raising money for the company. One could justify the potential.

There is a catch. We just don't know where the market will place it as of yet. My guess would be NGIO gets some credit but Generex may not see anywhere near the full value of it ownership %. Not uncommon for "holding companies" to be undervalued vs their assets.

Obviously news could change that perspective in a New York minute. Big pharma deals can make thousandaires into hundred thousandaires and sometimes millionaires in an instant.